paromamine profile

paromamine: RN given refers to (D)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

paromamine : An aminoglycoside that is 4alpha,6alpha-diaminocyclohexane-1beta,2alpha,3beta-triol in which the pro-R hydroxy group has been converted into its 2-amino-alpha-D-glucoside derivative. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	439560
CHEMBL ID	606552
CHEBI ID	7933
SCHEMBL ID	14495298
MeSH ID	M0047814

Synonym
wgk534pm7q ,
d-streptamine, 4-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl)-2-deoxy-
unii-wgk534pm7q
C01743
534-47-4
paromamine
neomycin d
(2r,3s,4r,5r,6s)-5-amino-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol
CHEMBL606552
chebi:7933 ,
4-o-(2-amino-2-deoxy-alpha-d-glucopyranosyl)-2-deoxy-d-streptamine
(1r,2r,3s,4r,6s)-4,6-diamino-2,3-dihydroxycyclohexyl 2-amino-2-deoxy-alpha-d-glucopyranoside
(1r)-o4-(2-amino-2-deoxy-alpha-d-glucopyranosyl)-2-deoxy-streptamine
SCHEMBL14495298
d5e ,
Q27107621
DTXSID20968057
4,6-diamino-2,3-dihydroxycyclohexyl 2-amino-2-deoxyhexopyranoside
4-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl)-2-deoxy-d-streptamine
d-streptamine, 4-o-(2-amino-2-deoxy-.alpha.-d-glucopyranosyl)-2-deoxy-
4-o-.alpha.-d-glucosaminyl-2-deoxystreptamine
gentamine a
.alpha.-d-glucopyranoside, 2-deoxy-d-streptamine-4 2-amino-2-deoxy-
neomycin sulfate impurity d [ep impurity]

Excerpt	Reference	Relevance
"Paromamine is a vital and common intermediate in the biosynthesis of 4,5 and 4,6-disubstituted 2-deoxystreptamine (DOS)-containing aminoglycosides. "	( Biosynthesis of paromamine derivatives in engineered Escherichia coli by heterologous expression. Kurumbang, NP; Liou, K; Sohng, JK, 2010)	2.15

Class	Description
aminoglycoside
primary amino compound	A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
triamine	Any polyamine that contained three amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (21)

Assay ID	Title	Year	Journal	Article
AID774229	Antibacterial activity against fluoroquinolone-resistant Staphylococcus aureus 1199B expressing NorA efflux pump after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID487947	Induction of ribosome to readthrough in-frame renilla/firefly TGA codon transfected in rabbit reticulocyte at 5 to 20 uM after 16 hrs dual-luciferase reporter gene assay	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations.
AID774215	Antibacterial activity against Escherichia coli ATCC 25922 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774227	Antibacterial activity against 14- and 15-membered macrolide-resistant Staphylococcus aureus expressing MsrA efflux pump after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID2940	Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli	2001	Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2	Which aminoglycoside ring is most important for binding? A hydropathic analysis of gentamicin, paromomycin, and analogues.
AID774222	Antibacterial activity against vancomycin-resistant Staphylococcus aureus VRS2 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774213	Antibacterial activity against Escherichia coli L58058.1 expressing ANT2''-1A after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774224	Antibacterial activity against Staphylococcus aureus expressing aminoglycoside-4'-O-phosphoryltransferase after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID1303150	Binding affinity to decoding site rRNA of ribosome in Escherichia coli using Escherichia coli S30 circular DNA assessed as inhibition of translation incubated for 20 mins by luciferase reporter gene based coupled transcription/translation assay	2016	ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4	Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations.
AID774226	Antibacterial activity against Staphylococcus aureus expressing aminoglycoside-6'-N-acetyltransferase/2''-O-phosphoryltransferase after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774220	Antibacterial activity against Acinetobacter lwoffii AI.88-483 expressing APH3'-6A after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774228	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774217	Antibacterial activity against Pseudomonas aeruginosa PA22 (PT629) expressing MexXY after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774214	Antibacterial activity against Escherichia coli PAZ505H8101 expressing AAC6'-1B after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774221	Antibacterial activity against Acinetobacter lwoffii ATCC 17925 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774218	Antibacterial activity against Pseudomonas aeruginosa F03 expressing AAC6'-2A after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774225	Antibacterial activity against Staphylococcus aureus expressing aminoglycoside-3'-O-phosphoryltransferase after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774216	Antibacterial activity against Klebsiella pneumoniae ATCC 700603 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID774223	Antibacterial activity against healthcare-acquired methicillin-resistant Staphylococcus aureus ATCC 33592 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
AID487946	Induction of ribosome to readthrough in-frame renilla/firefly TGA codon transfected in rabbit reticulocyte at 200 to 600 uM after 16 hrs dual-luciferase reporter gene assay	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations.
AID774219	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by geometric microdilution method	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (11.11)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (27.78)	29.6817
2010's	10 (55.56)	24.3611
2020's	1 (5.56)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	2.05	1	cyclitol; hexol
gentamicin Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.	2.04	1
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	2.76	3	kanamycins	bacterial metabolite
framycetin Framycetin: A component of NEOMYCIN that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). framycetin : A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.	3.12	5	aminoglycoside	allergen; antibacterial drug; Escherichia coli metabolite
uridine diphosphate glucose Uridine Diphosphate Glucose: A key intermediate in carbohydrate metabolism. Serves as a precursor of glycogen, can be metabolized into UDPgalactose and UDPglucuronic acid which can then be incorporated into polysaccharides as galactose and glucuronic acid. Also serves as a precursor of sucrose lipopolysaccharides, and glycosphingolipids.. UDP-alpha-D-glucose : The alpha-anomer of UDP-alpha-D-glucose. It is used in nucleotide sugars metabolism.	2.05	1	UDP-D-glucose	fundamental metabolite
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	2.07	1	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
ribostamycin Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).	2	1	amino cyclitol glycoside; aminoglycoside antibiotic	antibacterial drug; antimicrobial agent; metabolite
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	2.99	4	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	2.08	1	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
neamine neamine: fragment of NEOMYCIN B; structure in first source. neamine : 2-Deoxy-D-streptamine glycosylated at the 4-oxygen with a 6-amino-alpha-D-glucosaminyl group.	7.74	3	2,6-dideoxy-alpha-D-glucoside; aminoglycoside	antibacterial agent
lividomycin [no description available]	2.06	1	lividomycins	metabolite
antibiotic g 418 antibiotic G 418: from Micromonospora rhodorangea	2.05	1
paromomycin Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.	2.92	4	amino cyclitol glycoside; aminoglycoside antibiotic	anthelminthic drug; antibacterial drug; antiparasitic agent; antiprotozoal drug
2-deoxystreptamine 2-deoxystreptamine: RN given refers to parent cpd; structure.. 2-deoxystreptamine : An amino cyclitol consisting of scyllo-inositol with the hydroxy groups at positions 1 and 3 replaced by unsubstituted amino groups and that at position 2 replaced by hydrogen.	2.74	3
bekanamycin bekanamycin: kanendomycin is the sulfate of bekanamycin; RN given refers to parent cpd; structure	2.45	2	kanamycins
nadp [no description available]	2.15	1
apramycin apramycin : An aminoglycoside that is 2-deoxystreptamine that is substituted on the oxygen at position 4 by an (8R)-2-amino-8-O-(4-amino-4-deoxy-alpha-D-glucopyranosyl)-2,3,7-trideoxy-7-(methylamino)-D-glycero-alpha-D-allo-octodialdo-1,5:8,4-dipyranos-1-yl) group.	2.54	2	2-deoxystreptamine derivative; aminoglycoside; organic heterobicyclic compound	antibacterial drug; antimicrobial agent
gentamicin sulfate [no description available]	2.47	2
2-deoxyinosose 2-deoxyinosose: structure given in first source; an early intermediate in the biosynthesis of 2-deoxystreptamine	2.05	1
s-adenosylmethionine (R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.	7.59	2	organic cation; sulfonium compound	coenzyme; cofactor; human metabolite; micronutrient; Mycoplasma genitalium metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
gentamicin a gentamicin A: see also records for gentamicin B and gentamicin C; structure given in first source	2.04	1

Condition	Relationship Strength	Studies
Becker Muscular Dystrophy [description not available]	2.05	1
Genetic Diseases [description not available]	2.47	2
Deafness-Retinitis Pigmentosa Syndrome [description not available]	2.05	1
Cystic Fibrosis of Pancreas [description not available]	2.05	1
alpha-L-Iduronidase Deficiency [description not available]	2.05	1
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	2.05	1
Mucopolysaccharidosis I Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (IDURONIDASE) and characterized by progressive physical deterioration with urinary excretion of DERMATAN SULFATE and HEPARAN SULFATE. There are three recognized phenotypes representing a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include DWARFISM; hepatosplenomegaly; thick, coarse facial features with low nasal bridge; corneal clouding; cardiac complications; and noisy breathing.	2.05	1
Muscular Dystrophy, Duchenne An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)	2.05	1
Genetic Diseases, Inborn Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero.	2.47	2

paromamine

Description

Cross-References

Synonyms (24)

Research Excerpts

Overview

Drug Classes (3)

Bioassays (21)

Research

Studies (18)

Market Indicators

Research Demand Index: 11.47

Study Types

paromamine

Description

Cross-References

Synonyms (24)

Research Excerpts

Overview

Drug Classes (3)

Bioassays (21)

Research

Studies (18)

Market Indicators

Research Demand Index: 11.47

Study Types

Related Drugs (21)

Related Conditions (9)